This inventor holds 2 USPTO granted patents. Top assignee: Lihpao Life Science Corp.. Active years: 2018-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2020
Title: Teh-Ying Chou: Innovator in EGFR-TKI Treatment Evaluation
Introduction
Teh-Ying Chou is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical science, particularly in the evaluation of treatments for cancer. With a total of 2 patents, his work focuses on improving patient outcomes through innovative methodologies.
Latest Patents
Teh-Ying Chou's latest patents include a method for evaluating the efficacy of an EGFR-TKI treatment. This invention provides a systematic approach to assess the effectiveness of the treatment by identifying the V384D mutation in patients. By recognizing this mutation, healthcare providers can estimate the efficacy of the EGFR-TKI treatment and the progression-free survival of the subject after treatment.
Career Highlights
Chou is associated with Lihpao Life Science Corporation, where he applies his expertise in developing advanced medical solutions. His work is instrumental in enhancing the understanding of cancer treatments and their effectiveness.
Collaborations
Teh-Ying Chou collaborates with Chun-Ming Tsai, contributing to the advancement of research in the field of life sciences. Their partnership aims to innovate and refine treatment methodologies for better patient care.
Conclusion
Teh-Ying Chou's contributions to the medical field through his patents and collaborations highlight his commitment to improving cancer treatment evaluation. His innovative methods pave the way for enhanced patient outcomes and further research in the area.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile